Project description
Cell replacement therapy for Parkinson's disease
Parkinson's disease (PD) is a progressive neurodegenerative disorder characterised by the loss of midbrain dopaminergic neurons (mDAs). With existing treatments for PD being only palliative, replacement therapy using mDAs generated by human pluripotent stem cells (hPSCs) has spurred great interest. The scope of the EU-funded PreciseCellPD project is to improve the in vitro hPSC differentiation process so that it generates more substantia nigra neurons, which are the required cells for transplantation. To achieve this, scientists will investigate the transcription factors and regulators that control substantia nigra neuron specification in vitro from hPSCs.
Objective
Parkinson’s disease (PD) is a progressive incurable neurodegenerative disorder characterized by the loss of substantia nigra neurons (A9/SNs), a subset of midbrain dopaminergic neurons (mDAs) that are required for functional re-innervation of the striatum. Current treatments for PD are symptomatic and do not prevent disease progression. Proof-of-concept clinical studies using human fetal midbrain tissue for transplantation have shown that replacement of mDAs can change the course of PD. Human pluripotent stem cells (hPSCs) are currently used to generate mDAs for cell replacement therapy in clinical trials. However, our single-cell RNA-sequencing analysis of these preparations revealed that they comprise a complex mixture of cell types, including mDAs but also excessive vascular progenitor-like cells and serotonin neurons, thought to drive dyskinesias.
Selective generation of A9/SNs for PD cell replacement therapy remains thus a major challenge. Here I propose to identify how human adult A9/SNs are generated in order to develop a novel cell type-specific precision cell replacement therapy for PD. I hypothesize that a yet undefined network of transcription factors and regulators control A9/SN subtype specification, and that such factors can be used to engineer A9/SNs starting from hPSCs or astrocytes, moving the field beyond the state of the art.
This will be achieved by: 1) Using cutting-edge CRISPR and single cell methodologies to identify the factors controlling the specification of human A9/SNs; and 2) developing two novel cell replacement strategies for PD, involving either transplantation of hPSC-derived progenitors forward-programmed into A9/SNs or reprogramming of endogenous striatal glia in situ into A9/SNs, using a method we recently developed.
I expect PreciseCellPD will generate groundbreaking knowledge of the mechanisms controlling the generation of human A9/SNs and will set the basis of a novel and transformative precision cell replacement therapy for PD
Fields of science
Programme(s)
Topic(s)
Funding Scheme
ERC-ADG - Advanced GrantHost institution
17177 Stockholm
Sweden